Regional Observation of the Metabolic Syndrome

AstraZeneca1,600 enrolled

Overview

The aim of the study, is to assess the prevalence of metabolic syndrome in Italy on a regional basis, defined according to National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) guidelines criteria.

Study Type

OBSERVATIONAL

Enrollment

1,600

Conditions

Metabolic Syndrome

Eligibility

Sex: ALLMin age: 40 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Laboratory analysis (lipidic profile and glycemia) performed in the last year Exclusion Criteria: * Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study * Pregnancy or breast feeding * Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs

Locations (1)

Research Site

Torino, Italy

Outcomes

Primary Outcomes

Prevalence of metabolic syndrome in primary care population

Time frame: At visit

Concomitant presence of other cardiovascular (CV) risk factors.

Time frame: At visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.